Peptides for Cardiovascular

8 research peptides are currently studied for cardiovascular. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.

Semaglutide is a GLP-1 receptor agonist that has received FDA approval for multiple indications, including type 2 diabetes under the brand name Ozempic, chronic weight management as Wegovy, and non-cirrhotic steatohepatitis (MASH) also as Wegovy. Notably, semaglutide has been shown to induce significant weight loss and enhance glycemic control, with clinical trials indicating a reduction in body weight by an average of 15% in participants. Studies have also highlighted its cardiovascular benefits, suggesting a decrease in major adverse cardiovascular events. However, as there is no generic version available, the FDA has cautioned against counterfeit products, emphasizing the importance of sourcing from reputable suppliers.

Liraglutide, developed by Novo Nordisk, is another GLP-1 receptor agonist that holds FDA approval for treating type 2 diabetes as Victoza and for chronic weight management as Saxenda. It was the first of its class to gain approval for obesity management. Clinical studies have demonstrated that liraglutide can lead to clinically significant weight loss, with an average reduction of about 8-10% of body weight in obese individuals. Additionally, liraglutide has been shown to improve glycemic control, with evidence suggesting reductions in HbA1c levels. Its cardiovascular implications have also been explored, indicating a potential reduction in cardiovascular risk factors, although further research is warranted to fully elucidate these effects.

Dulaglutide is a GLP-1 analog that functions as a fusion protein, linking a GLP-1 peptide to a modified human IgG4 Fc fragment, which extends its half-life to approximately five days. This characteristic facilitates once-weekly administration, enhancing patient compliance. Approved by the FDA for type 2 diabetes, dulaglutide has been associated with effective glycemic control and clinically meaningful weight loss, with studies reporting an average weight reduction of 6-9%. Moreover, cardiovascular outcomes have been positively assessed, with trials indicating a reduction in major cardiovascular events in patients with type 2 diabetes. However, its safety profile remains an area of ongoing investigation, particularly in diverse populations.

Albiglutide, marketed as Tanzeum in the U.S. and Eperzan in Europe, was a once-weekly GLP-1 receptor agonist that combined two modified GLP-1 sequences fused to human albumin. Despite its withdrawal from the market in July 2018 due to commercial reasons rather than safety concerns, albiglutide's cardiovascular benefits were highlighted in the HARMONY Outcomes trial, which demonstrated a reduction in major adverse cardiovascular events. The peptide effectively lowered HbA1c levels in individuals with type 2 diabetes, supporting its role in glycemic management. While the withdrawal limits its availability for further research, the findings from clinical studies continue to inform the understanding of GLP-1 receptor agonists in cardiovascular health.

Cardiogen (Ala-Glu-Asp-Arg, AEDR) is a synthetic tetrapeptide belonging to the Khavinson bioregulatory peptide family, primarily investigated in animal and preclinical models. Proposed for cardiac regeneration and addressing cardiovascular aging, Cardiogen is believed to modulate gene expression in cardiomyocytes, which may enhance contractile function and reduce age-related cardiac fibrosis. While preliminary studies suggest potential benefits in improving cardiac function among the elderly, most published research is located within Russian biogerontology literature, highlighting the need for further validation through rigorous clinical trials in broader populations.

Vesilute (Lys-Glu-Asp, KED) is a synthetic tripeptide, with a molecular weight of approximately 390.4 g/mol, belonging to the Khavinson bioregulatory peptide family. It has been primarily studied in Russian literature, where it is proposed to function as a vascular-specific bioregulator aimed at restoring endothelial function and mitigating atherosclerotic changes associated with aging. Preclinical studies suggest that Vesilute may improve vascular elasticity and reduce endothelial dysfunction, although the evidence remains largely anecdotal and lacks robust clinical validation. The primary claims surrounding Vesilute emphasize its potential to enhance vascular function in aging populations, yet the limited availability of peer-reviewed research and reliance on non-English publications contribute to a low evidence rating of D.

B7-33 is a novel, single-chain analog of human relaxin-2, specifically designed to engage the RXFP1 receptor while simplifying manufacturing processes compared to the native two-chain hormone. Research indicates that B7-33 exhibits vasodilatory and anti-fibrotic properties in preclinical models, suggesting its potential for cardiovascular protection. The peptide's ability to modulate vascular tone and inhibit fibrosis could have significant implications for conditions characterized by vascular dysfunction. However, the current evidence is primarily derived from animal studies, and the transition to human application remains untested. As a result, B7-33 is assigned a D evidence rating, reflecting the need for further investigation to substantiate its efficacy and safety in clinical settings.

Vesugen (Lys-Glu-Asp) is another synthetic tripeptide from the Khavinson bioregulator series, aimed at normalizing vascular endothelial function through tissue-specific gene regulation. While it is posited to improve overall vascular health, the supporting evidence is limited and primarily derived from preclinical studies. The claims surrounding Vesugen focus on its potential to enhance endothelial function, though comprehensive clinical data validating these claims are lacking. Given the nascent stage of research and the absence of extensive peer-reviewed studies, Vesugen carries a D evidence rating. This underscores the necessity for further exploration to clarify its mechanisms and potential therapeutic applications in cardiovascular health.